CoChat

A multi-center, late phase II clinical trial of Genexol® (paclitaxel) and cisplatin for patients with advanced gastric cancer

Park, Sook, Oh, Do-Youn, Kim, Dong-Wan, Kim, Tae-You, Heo, Dae, Bang, Yung-Jue, Kim, Noe, Kang, Won, Kim, Heung-Tae, Im, Seock-Ah, Suh, Jae-Hong, Kim, Hark-Kyun, Kim, Hoon-Kyo · 2004 · Oncology Reports
Cited by 41

The DOI matches its Crossref record.

Abstract

Because of unsatisfactory treatment results with 5-fluorouracil-based palliative combination chemotherapy for advanced gastric cancer, the evaluation of new effective and well-tolerated regimens is needed. We conducted a multi-center, late phase II trial to evaluate the efficacy and safety of Genexol (a paclitaxel formulation) combined chemotherapy with cisplatin in patients with previously untreated metastatic or unresectable measurable gastric adenocarcinoma. All patients were between 18 and 75 years of age, with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1, and had an adequate baseline major organ function. Genexol 175 mg/m(2) was administered as a 3-h infusion, followed by cisplatin 75 mg/m(2) as an intravenous infusion day 1, once every 3 weeks. Thirty-six patients were enrolled from 7 hospitals between November 2002 and April 2003. Of these, 33 patients were assessable for efficacy and 35 for toxicity. Based on an intent-to-treat analysis, 16 patients (46%) achieved a partial response, 7 (20%) stable disease, and 10 (29%) progressed, giving an overall response rate of 46% (95% CI, 29% to 63%). The median duration of response was 7.1 months (95% CI, 6.3 to 7.9 months), and the median time to progression and overall survival were 4.9 months (95% CI, 3.2 to 6.6 months) and 13.8 months (95% CI, 10.8 to 16.8 months), respectively. The major toxicity was neutropenia, with grade 3/4 intensity in 10 patients (29%). However, no febrile neutropenia occurred, and non-hematologic toxicity was usually mild. Grade 3/4 toxicities included nausea (9% of the patients), vomiting (9%), peripheral neuropathy (9%), alopecia (9%), and myalgia (6%). In conclusion, the combination of Genexol and cisplatin was found to be an active and relatively well-tolerated regimen for the treatment of advanced gastric carcinoma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3892/or.12.5.1059

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 41

Metadata

Authors
Park, S., Oh, D.-Y., Kim, D.-W., Kim, T.-Y., Heo, D., Bang, Y.-J., Kim, N., Kang, W., Kim, H.-T., Im, S.-A., Suh, J.-H., Kim, H.-K., & Kim, H.-K.
Venue
Oncology Reports
Published
2004-11-01
Volume
12
Issue
5
Pages
1059-64
ISSN
  • 1021-335X (ISSN-L)
  • 1791-2431
OpenAlex
W1974116789
Cited by
41
References
0
FWCI
3.12
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A multi-center, late phase II clinical trial of Genexol® (paclitaxel) and cisplatin for patients with advanced gastric cancer. https://app.cochat.ai/papers/10.3892/or.12.5.1059
The paper
Park, S., Oh, D.-Y., Kim, D.-W., Kim, T.-Y., Heo, D., Bang, Y.-J., Kim, N., Kang, W., Kim, H.-T., Im, S.-A., Suh, J.-H., Kim, H.-K., & Kim, H.-K. (2004). A multi-center, late phase II clinical trial of Genexol® (paclitaxel) and cisplatin for patients with advanced gastric cancer. Oncology Reports. https://doi.org/10.3892/or.12.5.1059

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.